These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 39029781)

  • 1. Establishment of advanced tumor organoids with emerging innovative technologies.
    Mao Y; Hu H
    Cancer Lett; 2024 Aug; 598():217122. PubMed ID: 39029781
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Appendiceal Cancer Patient-Specific Tumor Organoid Model for Predicting Chemotherapy Efficacy Prior to Initiation of Treatment: A Feasibility Study.
    Votanopoulos KI; Mazzocchi A; Sivakumar H; Forsythe S; Aleman J; Levine EA; Skardal A
    Ann Surg Oncol; 2019 Jan; 26(1):139-147. PubMed ID: 30414038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Patient-Derived Organoids for Precision Cancer Immunotherapy.
    Grönholm M; Feodoroff M; Antignani G; Martins B; Hamdan F; Cerullo V
    Cancer Res; 2021 Jun; 81(12):3149-3155. PubMed ID: 33687948
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The establishment of kidney cancer organoid line in drug testing.
    Tse RT; Wong CY; Ding X; Cheng CK; Chow C; Chan RC; Ng JH; Tang VW; Chiu PK; Teoh JY; Wong N; To KF; Ng CF
    Cancer Med; 2024 Jun; 13(12):e7432. PubMed ID: 38923304
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Establishment of 2.5D organoid culture model using 3D bladder cancer organoid culture.
    Abugomaa A; Elbadawy M; Yamanaka M; Goto Y; Hayashi K; Mori T; Uchide T; Azakami D; Fukushima R; Yoshida T; Shibutani M; Yamashita R; Kobayashi M; Yamawaki H; Shinohara Y; Kaneda M; Usui T; Sasaki K
    Sci Rep; 2020 Jun; 10(1):9393. PubMed ID: 32523078
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug Sensitivity Assays of Human Cancer Organoid Cultures.
    Francies HE; Barthorpe A; McLaren-Douglas A; Barendt WJ; Garnett MJ
    Methods Mol Biol; 2019; 1576():339-351. PubMed ID: 27628132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor organoids: Opportunities and challenges to guide precision medicine.
    Veninga V; Voest EE
    Cancer Cell; 2021 Sep; 39(9):1190-1201. PubMed ID: 34416168
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine.
    Qu S; Xu R; Yi G; Li Z; Zhang H; Qi S; Huang G
    Mol Biomed; 2024 Feb; 5(1):6. PubMed ID: 38342791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Applications of patient-derived tumor xenograft models and tumor organoids.
    Yoshida GJ
    J Hematol Oncol; 2020 Jan; 13(1):4. PubMed ID: 31910904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Advances and Applications of Cancer Organoids in Drug Screening and Personalized Medicine.
    Yang Y; Kong Y; Cui J; Hou Y; Gu Z; Ma C
    Stem Cell Rev Rep; 2024 Jul; 20(5):1213-1226. PubMed ID: 38532032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human-cell-derived organoids as a new ex vivo model for drug assays in oncology.
    Mebarki M; Bennaceur A; Bonhomme-Faivre L
    Drug Discov Today; 2018 Apr; 23(4):857-863. PubMed ID: 29428171
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cancer research using organoid technology.
    Kretzschmar K
    J Mol Med (Berl); 2021 Apr; 99(4):501-515. PubMed ID: 33057820
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Patient-derived cancer organoids for drug screening: Basic technology and clinical application.
    Ren X; Chen W; Yang Q; Li X; Xu L
    J Gastroenterol Hepatol; 2022 Aug; 37(8):1446-1454. PubMed ID: 35771719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Exploring Tumor-Immune Interactions in Co-Culture Models of T Cells and Tumor Organoids Derived from Patients.
    Jeong SR; Kang M
    Int J Mol Sci; 2023 Sep; 24(19):. PubMed ID: 37834057
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling liver cancer and therapy responsiveness using organoids derived from primary mouse liver tumors.
    Cao W; Liu J; Wang L; Li M; Verstegen MMA; Yin Y; Ma B; Chen K; Bolkestein M; Sprengers D; van der Laan LJW; Doukas M; Kwekkeboom J; Smits R; Peppelenbosch MP; Pan Q
    Carcinogenesis; 2019 Mar; 40(1):145-154. PubMed ID: 30289434
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor Organoid as a Drug Screening Platform for Cancer Research.
    Arani RM; Yousefi N; Hamidieh AA; Gholizadeh F; Sisakht MM
    Curr Stem Cell Res Ther; 2024; 19(9):1210-1250. PubMed ID: 37855289
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Circulating tumor cell-derived organoids: Current challenges and promises in medical research and precision medicine.
    Praharaj PP; Bhutia SK; Nagrath S; Bitting RL; Deep G
    Biochim Biophys Acta Rev Cancer; 2018 Apr; 1869(2):117-127. PubMed ID: 29360544
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Model of Patient-Specific Immune-Enhanced Organoids for Immunotherapy Screening: Feasibility Study.
    Votanopoulos KI; Forsythe S; Sivakumar H; Mazzocchi A; Aleman J; Miller L; Levine E; Triozzi P; Skardal A
    Ann Surg Oncol; 2020 Jun; 27(6):1956-1967. PubMed ID: 31858299
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Head and neck cancer organoids established by modification of the CTOS method can be used to predict in vivo drug sensitivity.
    Tanaka N; Osman AA; Takahashi Y; Lindemann A; Patel AA; Zhao M; Takahashi H; Myers JN
    Oral Oncol; 2018 Dec; 87():49-57. PubMed ID: 30527243
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Spheroids to organoids: Solid cancer models for anticancer drug discovery].
    Alzeeb G; Corcos L; Le Jossic-Corcos C
    Bull Cancer; 2022 Jan; 109(1):49-57. PubMed ID: 34848046
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.